What is apparent from the posts here, many do not understand that MAST was never designed to enter a PH2 Trial. The expansion cohorts (Bile Duct) were the PH2 candidates! The reason IMU is chasing rare unmet needs in cancer to reduce the costs and time to approvals.
ONCARLYTICS may never need to do so phase 3 trials as IMU might never seek approval for Oncarlytics as a designated therapy for a specified cancer. It might just be an adjunct therapy to support Azercel!
It just might get a GRAS type status. Azercel might get all the approvals but it needs a dose of ONCARLYTICS to work effectively.
We have a team of experts on the job. I would not be buying or selling my shares on the advice of the HotCopper experts who have never worked in this field and have definitely not achieved an elite level of expertise!
This is extremely complex work hence the high remuneration. And My view is this world class team are still progressing towards the end goal “a universal vaccine against cancer”. This is why Yuman Fong is so excited about Azer-Cel and Oncarlytics going into the clinic in 2025!
IMU Price at posting:
2.4¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)